Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada Outlines “Patient-Oriented Research” Strategy

Executive Summary

Canada is developing a comparative effectiveness research strategy that, like the Patient-Centered Outcomes Research Institute in the U.S., is targeting a patient-focused approach that aims to ensure that patients get the right treatments at the right times.

You may also be interested in...



PCORI Seeks Public Input On Definition Of "Patient-Centered Outcomes Research"

Outreach efforts include web-based survey as the public/private Patient-Centered Outcomes Research Institute looks to finish a key part of its foundation and move forward on research activities.

PCORI Is A “Transformative Opportunity” – Chairman Washington

NEW YORK – To a casual observer, it may seem that the Patient-Centered Outcomes Research Institute is moving slowly, but for Eugene Washington, the chairman of PCORI’s Board of Governors, the group’s deliberations reflect the goal of having the body be more than just another driver of comparative effectiveness research.

FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees

Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel